Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Serplulimab Plus Bevacizumab and Chemotherapy for Left-Sided, KRAS/NRAS/BRAF Wild-Type Colorectal Cancer After First-Line Anti-EGFR Therapy (SALVAGE)

16 novembre 2026 mis à jour par: Jingdong Zhang, China Medical University, China

A Randomized, Controlled, Multicenter, Phase 2 Clinical Study of Serplulimab Combined With Bevacizumab and Chemotherapy in Patients With Left-Sided, KRAS/NRAS/BRAF Wild-Type Colorectal Cancer Who Failed First-Line Anti-EGFR Monoclonal Antibody Therapy

This is a prospective, multicenter, randomized, controlled Phase 2 clinical study to evaluate the effectiveness and safety of adding serplulimab (an immunotherapy drug that targets PD-1) to standard second-line treatment with bevacizumab and chemotherapy. The study enrolls adult patients with advanced or metastatic, left-sided colorectal cancer whose tumors are microsatellite stable (MSS) or mismatch repair proficient (pMMR) and carry no mutations in the KRAS, NRAS, or BRAF genes (wild-type), and whose cancer worsened after first-line treatment containing an anti-EGFR antibody and chemotherapy.

Approximately 96 eligible participants will be randomly assigned in a 1:1 ratio to one of two treatment groups. Participants in the experimental group (Arm A) will receive serplulimab plus bevacizumab and chemotherapy every 3 weeks, while participants in the control group (Arm B) will receive bevacizumab and chemotherapy every 3 weeks. In both groups, the chemotherapy regimen is chosen based on prior first-line therapy: participants who previously received irinotecan will receive CapeOX (oxaliplatin and capecitabine), and those who previously received oxaliplatin will receive mXELIRI (irinotecan and capecitabine). Treatment will continue until disease progression, unacceptable side effects, withdrawal of consent, or study completion.

Aperçu de l'étude

Description détaillée

Scientific Rationale:Approximately 95% of patients with advanced or metastatic colorectal cancer (mCRC) harbor microsatellite stable (MSS) or mismatch repair-proficient (pMMR) tumors, a population in which single-agent immune checkpoint inhibitors have demonstrated minimal clinical activity. Preclinical and clinical evidence suggests that cytotoxic chemotherapy (by inducing immunogenic cell death and enhancing antigen presentation) and anti-angiogenic therapy such as bevacizumab (by promoting cytotoxic T-lymphocyte infiltration while reducing regulatory T cells, myeloid-derived suppressor cells, and tumor-associated macrophages) can reprogram the immunosuppressive tumor microenvironment and synergize with PD-1 blockade. Serplulimab (HLX10), a humanized anti-PD-1 IgG4 monoclonal antibody, combined with bevacizumab and XELOX previously demonstrated a substantial progression-free survival (PFS) improvement in first-line mCRC (ASTRUM-015 study). This study investigates whether adding serplulimab to standard second-line bevacizumab plus chemotherapy improves clinical outcomes specifically in patients with left-sided, RAS/BRAF wild-type, MSS/pMMR mCRC following disease progression on first-line anti-EGFR monoclonal antibody therapy.

Type d'étude

Interventionnel

Inscription (Estimé)

96

Phase

  • Phase 2

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Lieux d'étude

    • Liaoning
      • Shenyang, Liaoning, Chine, 11000
        • Liaoning Provincial Cancer Hospital

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • Voluntarily agree to participate in the study and sign the written informed consent form.
  • Pathologically confirmed left-sided, microsatellite stable (MSS) or mismatch repair-proficient (pMMR), KRAS/NRAS/BRAF wild-type advanced metastatic colorectal adenocarcinoma.
  • Disease progression following prior first-line standard therapy (anti-EGFR monoclonal antibody combined with chemotherapy).
  • Aged >= 18 years, regardless of sex.
  • Expected survival >= 3 months.
  • Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.
  • At least one measurable target lesion according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1).
  • Adequate hematologic function within 14 days prior to enrollment: hemoglobin >= 90 g/L (without blood transfusion within 14 days), absolute neutrophil count >= 1.5 x 10^9/L, and platelet count >= 80 x 10^9/L.
  • Adequate hepatic and renal function within 14 days prior to enrollment: total bilirubin <= 1.5 x upper limit of normal (ULN); alanine aminotransferase (ALT) and aspartate aminotransferase (AST) <= 2.5 x ULN (or <= 5 x ULN in patients with liver metastases); and endogenous creatinine clearance >= 60 mL/min (calculated using the Cockcroft-Gault formula).
  • Left ventricular ejection fraction (LVEF) >= 50% as assessed by Doppler echocardiography.
  • Negative serum pregnancy test within 14 days prior to treatment initiation for women of childbearing potential; eligible male and female patients of childbearing potential must agree to use reliable contraceptive methods (hormonal methods, barrier methods, or abstinence) with their partners during the study and for at least 6 months after the last dose of study treatment.

Exclusion Criteria:

  • Currently participating in another interventional drug clinical trial (non-interventional clinical studies are permitted).
  • History of or concurrent other malignancies, except for cured basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder cancer, or carcinoma in situ of the cervix or breast.
  • Known central nervous system (CNS) metastases (for patients with clinically suspected CNS metastases, CT or MRI must be performed within 28 days prior to treatment initiation to exclude CNS metastases).
  • Clinically symptomatic pleural effusion or ascites requiring clinical intervention.
  • Current use of immunosuppressive agents for any reason, or systemic corticosteroid therapy for immunosuppressive purposes (at a dose > 10 mg/day of prednisone or equivalent).
  • Presence of any active autoimmune disease (including, but not limited to, autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis, hepatitis, hypophysitis, vasculitis, or nephritis).
  • History of organ transplantation.
  • Concurrent hyperthyroidism.
  • Concurrent vitiligo.
  • History of inflammatory bowel disease (such as ulcerative colitis or Crohn's disease) or chronic diarrheal diseases (such as irritable bowel syndrome).
  • History of sarcoidosis or tuberculosis.
  • Active hepatitis B, active hepatitis C, or human immunodeficiency virus (HIV) infection.
  • Newly diagnosed angina pectoris within 3 months prior to screening or myocardial infarction within 6 months prior to screening; cardiac arrhythmia (including QTcF >= 450 ms in males or >= 470 ms in females) requiring long-term antiarrhythmic medication; or New York Heart Association (NYHA) Class >= II cardiac insufficiency.
  • Asthma requiring medical intervention with bronchodilators (patients with childhood asthma that has completely resolved and requires no intervention in adulthood may be included).
  • Infectious pneumonia, non-infectious pneumonia, interstitial pneumonia, or other pulmonary inflammation requiring corticosteroid therapy.
  • History of psychotropic substance abuse with inability to abstain, or psychiatric disorders.
  • Urinalysis showing urine protein >= 2+ and 24-hour urinary protein quantification > 1.0 g.
  • Known hereditary or acquired bleeding and thrombotic tendencies (such as hemophilia, coagulation disorders, thrombocytopenia, hypersplenism, etc.) or currently receiving thrombolytic or anticoagulant therapy.
  • Active bleeding or high risk of bleeding, such as significant bleeding tendency within 3 months prior to enrollment.
  • Other conditions judged by the investigator that may affect study results or lead to premature study discontinuation, such as substance abuse, severe illnesses (including psychiatric disorders such as epileptic seizures), or other medical, psychological, or social conditions that may compromise patient safety or compliance.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Arm A: Serplulimab Plus Bevacizumab and Chemotherapy

Participants receive serplulimab (300 mg, Day 1) plus bevacizumab (7.5 mg/kg, Day 1) and chemotherapy every 3 weeks (Q3W). The chemotherapy regimen is determined by prior first-line therapy: participants previously treated with an irinotecan-containing regimen receive CapeOX (oxaliplatin 130 mg/m2 on Day 1 plus capecitabine 1000 mg/m2 on Days 1-14, Q3W), while those previously treated with an oxaliplatin-containing regimen receive mXELIRI (irinotecan 200 mg/m2 on Day 1 plus capecitabine 800 mg/m2 on Days 1-14, Q3W). Local antitumor therapy (such as radiotherapy or radiofrequency ablation) for localized metastases is permitted. Treatment continues until disease progression, unacceptable toxicity, confirmed pregnancy, death, withdrawal of consent, loss to follow-up, or study termination, whichever occurs first.

Serplulimab (HLX10, Hansizhuang; manufactured by Shanghai Henlius Biotech, Inc.) is administered at a fixed dose of 300 mg on Day 1 of each 21-day (3-week) cycle. Treatment continues until disease progression, unacceptable toxicity, confirmed pregnancy, death, withdrawal of consent, loss to follow-up, or study termination, whichever occurs first.

Autres noms:
  • HLX10
  • Hansizhuang

Bevacizumab (Hanbeitai; manufactured by Shanghai Henlius Biotech, Inc.) is administered at a dose of 7.5 mg/kg on Day 1 of each 21-day (3-week) cycle. Treatment continues until disease progression, unacceptable toxicity, confirmed pregnancy, death, withdrawal of consent, loss to follow-up, or study termination, whichever occurs first.

Administered as part of the CapeOX regimen only to participants who previously received an irinotecan-containing first-line regimen. Oxaliplatin is given at a dose of 130 mg/m2 on Day 1 of each 21-day (3-week) cycle until disease progression, unacceptable toxicity, confirmed pregnancy, death, withdrawal of consent, loss to follow-up, or study termination, whichever occurs first.

Administered as part of the mXELIRI regimen only to participants who previously received an oxaliplatin-containing first-line therapy. Irinotecan is given at a dose of 200 mg/m2 on Day 1 of each 21-day (3-week) cycle until disease progression, unacceptable toxicity, confirmed pregnancy, death, withdrawal of consent, loss to follow-up, or study termination, whichever occurs first.

Administered on Days 1 to 14 of each 21-day (3-week) cycle, with the dose determined by the chemotherapy backbone assigned based on prior first-line therapy:

In the CapeOX regimen (for participants previously treated with an irinotecan-containing regimen): 1000 mg/m2 on Days 1-14, every 3 weeks.

In the mXELIRI regimen (for participants previously treated with an oxaliplatin-containing regimen): 800 mg/m2 on Days 1-14, every 3 weeks.

Treatment continues until disease progression, unacceptable toxicity, confirmed pregnancy, death, withdrawal of consent, loss to follow-up, or study termination, whichever occurs first.

Comparateur actif: Arm B: Bevacizumab Plus Chemotherapy

Participants receive bevacizumab (7.5 mg/kg, Day 1) plus chemotherapy every 3 weeks (Q3W). The chemotherapy regimen is determined by prior first-line therapy: participants previously treated with an irinotecan-containing regimen receive CapeOX (oxaliplatin 130 mg/m2 on Day 1 plus capecitabine 1000 mg/m2 on Days 1-14, Q3W), while those previously treated with an oxaliplatin-containing regimen receive mXELIRI (irinotecan 200 mg/m2 on Day 1 plus capecitabine 800 mg/m2 on Days 1-14, Q3W). Local antitumor therapy (such as radiotherapy or radiofrequency ablation) for localized metastases is permitted. Treatment continues until disease progression, unacceptable toxicity, confirmed pregnancy, death, withdrawal of consent, loss to follow-up, or study termination, whichever occurs first.

Bevacizumab (Hanbeitai; manufactured by Shanghai Henlius Biotech, Inc.) is administered at a dose of 7.5 mg/kg on Day 1 of each 21-day (3-week) cycle. Treatment continues until disease progression, unacceptable toxicity, confirmed pregnancy, death, withdrawal of consent, loss to follow-up, or study termination, whichever occurs first.

Administered as part of the CapeOX regimen only to participants who previously received an irinotecan-containing first-line regimen. Oxaliplatin is given at a dose of 130 mg/m2 on Day 1 of each 21-day (3-week) cycle until disease progression, unacceptable toxicity, confirmed pregnancy, death, withdrawal of consent, loss to follow-up, or study termination, whichever occurs first.

Administered as part of the mXELIRI regimen only to participants who previously received an oxaliplatin-containing first-line therapy. Irinotecan is given at a dose of 200 mg/m2 on Day 1 of each 21-day (3-week) cycle until disease progression, unacceptable toxicity, confirmed pregnancy, death, withdrawal of consent, loss to follow-up, or study termination, whichever occurs first.

Administered on Days 1 to 14 of each 21-day (3-week) cycle, with the dose determined by the chemotherapy backbone assigned based on prior first-line therapy:

In the CapeOX regimen (for participants previously treated with an irinotecan-containing regimen): 1000 mg/m2 on Days 1-14, every 3 weeks.

In the mXELIRI regimen (for participants previously treated with an oxaliplatin-containing regimen): 800 mg/m2 on Days 1-14, every 3 weeks.

Treatment continues until disease progression, unacceptable toxicity, confirmed pregnancy, death, withdrawal of consent, loss to follow-up, or study termination, whichever occurs first.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
9-Month Progression-Free Survival (PFS) Rate
Délai: At 9 months after treatment initiation

The proportion of participants who are alive and free of radiographic disease progression at 9 months after the initiation of study treatment. Tumor assessments are performed at baseline and every 6 weeks (±7 days) during treatment using contrast-enhanced CT or MRI according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1).

At 9 months after treatment initiation

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Progression-Free Survival (PFS)
Délai: From initiation of study treatment until disease progression or death, assessed every 6 weeks (±7 days) up to study completion (approximately 24 months)

Defined as the time from the initiation of study treatment to the first documented disease progression (evaluated by investigators according to RECIST v1.1) or death from any cause, whichever occurs first, estimated using the Kaplan-Meier method. Tumor assessments (contrast-enhanced CT or MRI) are performed at baseline and every 6 weeks (±7 days) thereafter.

From initiation of study treatment until disease progression or death, assessed every 6 weeks (±7 days) up to study completion (approximately 24 months)
Objective Response Rate (ORR)
Délai: From initiation of study treatment until disease progression or death, assessed every 6 weeks (±7 days) up to study completion (approximately 24 months)

The percentage of participants achieving a complete response (CR) or partial response (PR) as their best overall response, evaluated by investigators according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1). Tumor assessments (contrast-enhanced CT or MRI) are performed at baseline and every 6 weeks (±7 days) thereafter.

From initiation of study treatment until disease progression or death, assessed every 6 weeks (±7 days) up to study completion (approximately 24 months)
Disease Control Rate (DCR)
Délai: From initiation of study treatment until disease progression or death, assessed every 6 weeks (±7 days) up to study completion (approximately 24 months)

The percentage of participants achieving a complete response (CR), partial response (PR), or stable disease (SD) as their best overall response, evaluated by investigators according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1). Tumor assessments (contrast-enhanced CT or MRI) are performed at baseline and every 6 weeks (±7 days) thereafter.

From initiation of study treatment until disease progression or death, assessed every 6 weeks (±7 days) up to study completion (approximately 24 months)
Overall Survival (OS)
Délai: From enrollment until death from any cause, assessed every 3 months during the first year after treatment discontinuation and every 6 months thereafter up to study completion (approximately 24 months)

Defined as the time from enrollment to death from any cause, estimated using the Kaplan-Meier method. Participants who are still alive at the last follow-up will be censored at the date of last known survival.

From enrollment until death from any cause, assessed every 3 months during the first year after treatment discontinuation and every 6 months thereafter up to study completion (approximately 24 months)
Incidence and Severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)
Délai: From signing of informed consent through 30 days after the last dose of study treatment (or until initiation of new antitumor therapy, whichever occurs first)

Number and percentage of participants experiencing adverse events (AEs) and serious adverse events (SAEs), as well as clinically significant changes in laboratory tests, vital signs, 12-lead electrocardiograms, and echocardiograms. Toxicity severity is graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 (NCI-CTCAE v5.0).

From signing of informed consent through 30 days after the last dose of study treatment (or until initiation of new antitumor therapy, whichever occurs first)

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Estimé)

1 décembre 2026

Achèvement primaire (Estimé)

30 juin 2028

Achèvement de l'étude (Estimé)

30 juin 2029

Dates d'inscription aux études

Première soumission

16 novembre 2026

Première soumission répondant aux critères de contrôle qualité

16 novembre 2026

Première publication (Réel)

20 novembre 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

20 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

16 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner